FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2357754687> ?p ?o ?g. }

• W2357754687 abstract "Background. Available therapeutic surfactants are either animal-derived or non-protein-containing synthetic products. Animal-derived surfactants contain variable amounts of surfactant apoproteins, whereas the older-generation synthetic products contain only phospholipids and lack surfactant proteins (SPs). Both decrease morbidity and mortality rates associated with respiratory distress syndrome (RDS) among preterm infants, compared with placebo. However, excess mortality rates have been observed with non-protein-containing synthetic surfactants, compared with the animal-derived products. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved with the addition of peptides that are functional analogs of SPs. Lucinactant is a new synthetic peptide-containing surfactant that contains sinapultide, a novel, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human SP-B. It is completely devoid of animal-derived components. Objective. We hypothesized that the outcomes for premature infants treated with lucinactant and poractant alfa would be similar. Therefore, we compared lucinactant (Surfaxin; Discovery Laboratories, Doylestown, PA) with porcine-derived, poractant alfa (Curosurf;Chiesi Farmaceutici, Parma, Italy) in a trial to test for noninferiority. Methods. A total of 252 infants born between 24 and 28 weeks of completed gestation, with birth weights between 600 and 1250 g, were assigned randomly in a multicenter, multinational, noninferiority, randomized, controlled study to receive either lucinactant (n=124) or poractant alfa (n =128) within 30 minutes of life. The primary outcome was the incidence of being alive without bronchopulmonary dysplasia (BPD) through 28 days of age. Key secondary outcomes included death at day 28 and 36 weeks postmenstrual age (PMA), air leaks, neuroimaging abnormalities, and other complications related to either prematurity or RDS. An independent, international, data and safety monitoring committee monitored the trial. Results. The treatment difference between lucinactant and poractant alfa for survival without BPD through 28 days was 4.75%(95%confidence interval [CI]: -7.3%to 16.8%) in favor of lucinactant, with the lower boundary of the 95%CI for the difference, ie, -7.3%, being greater than the prespecified noninferiority margin of -14.5%. At 28 days, 45 of 119 infants given lucinactant were alive without BPD (37.8%; 95%CI: 29.1-46.5%), compared with 41 of 124 given poractant alfa (33.1%; 95%CI: 24.8-41.3%); at 36 weeks PMA, the rates were 64.7%and 66.9%, respectively. The corresponding mortality rate through day 28 for the lucinactant group was lower than that for the poractant alfa group (11.8%[95%CI: 6.0-17.6%] vs 16.1%[95%CI: 9.7-22.6%]), as was the rate at 36 weeks PMA (16%and 18.5%, respectively). There were no differences in major dosing complications. In addition, no significant differences were observed in the incidences of common complications of prematurity, including intraventricular hemorrhage (grades 3 and 4) and cystic periventricular leukomalacia (lucinactant: 14.3%; poractant alfa: 16.9%). Conclusions. Lucinactant and poractant alfa were similar in terms of efficacy and safety when used for the prevention and treatment of RDS among preterm infants. The ability to enhance the performance of a synthetic surfactant with the addition of a peptide that mimics the action of SP-B, such as sinapultide, brings potential advantages to exogenous surfactant therapy." @default.
• W2357754687 created "2016-06-24" @default.
• W2357754687 creator A5003024393 @default.
• W2357754687 date "2006-01-01" @default.
• W2357754687 modified "2023-09-26" @default.
• W2357754687 title "A multicenter,randomized,controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome" @default.
• W2357754687 hasPublicationYear "2006" @default.
• W2357754687 type Work @default.
• W2357754687 sameAs 2357754687 @default.
• W2357754687 citedByCount "0" @default.
• W2357754687 crossrefType "journal-article" @default.
• W2357754687 hasAuthorship W2357754687A5003024393 @default.
• W2357754687 hasConcept C126322002 @default.
• W2357754687 hasConcept C141071460 @default.
• W2357754687 hasConcept C141983124 @default.
• W2357754687 hasConcept C142724271 @default.
• W2357754687 hasConcept C168563851 @default.
• W2357754687 hasConcept C187212893 @default.
• W2357754687 hasConcept C204787440 @default.
• W2357754687 hasConcept C27081682 @default.
• W2357754687 hasConcept C2778376644 @default.
• W2357754687 hasConcept C2778721537 @default.
• W2357754687 hasConcept C2779234561 @default.
• W2357754687 hasConcept C54355233 @default.
• W2357754687 hasConcept C71924100 @default.
• W2357754687 hasConcept C86803240 @default.
• W2357754687 hasConceptScore W2357754687C126322002 @default.
• W2357754687 hasConceptScore W2357754687C141071460 @default.
• W2357754687 hasConceptScore W2357754687C141983124 @default.
• W2357754687 hasConceptScore W2357754687C142724271 @default.
• W2357754687 hasConceptScore W2357754687C168563851 @default.
• W2357754687 hasConceptScore W2357754687C187212893 @default.
• W2357754687 hasConceptScore W2357754687C204787440 @default.
• W2357754687 hasConceptScore W2357754687C27081682 @default.
• W2357754687 hasConceptScore W2357754687C2778376644 @default.
• W2357754687 hasConceptScore W2357754687C2778721537 @default.
• W2357754687 hasConceptScore W2357754687C2779234561 @default.
• W2357754687 hasConceptScore W2357754687C54355233 @default.
• W2357754687 hasConceptScore W2357754687C71924100 @default.
• W2357754687 hasConceptScore W2357754687C86803240 @default.
• W2357754687 hasLocation W23577546871 @default.
• W2357754687 hasOpenAccess W2357754687 @default.
• W2357754687 hasPrimaryLocation W23577546871 @default.
• W2357754687 hasRelatedWork W1993728497 @default.
• W2357754687 hasRelatedWork W1996242743 @default.
• W2357754687 hasRelatedWork W2003277279 @default.
• W2357754687 hasRelatedWork W2026731791 @default.
• W2357754687 hasRelatedWork W2057632519 @default.
• W2357754687 hasRelatedWork W2077973584 @default.
• W2357754687 hasRelatedWork W2132448456 @default.
• W2357754687 hasRelatedWork W2149985735 @default.
• W2357754687 hasRelatedWork W2275486242 @default.
• W2357754687 hasRelatedWork W2330822721 @default.
• W2357754687 hasRelatedWork W2418888548 @default.
• W2357754687 hasRelatedWork W2623858190 @default.
• W2357754687 hasRelatedWork W3003565346 @default.
• W2357754687 hasRelatedWork W3031743097 @default.
• W2357754687 hasRelatedWork W3041817764 @default.
• W2357754687 hasRelatedWork W3047979331 @default.
• W2357754687 hasRelatedWork W3104804986 @default.
• W2357754687 hasRelatedWork W3114109665 @default.
• W2357754687 hasRelatedWork W3131552727 @default.
• W2357754687 hasRelatedWork W2129596517 @default.
• W2357754687 isParatext "false" @default.
• W2357754687 isRetracted "false" @default.
• W2357754687 magId "2357754687" @default.
• W2357754687 workType "article" @default.